Beyond Air, Inc. XAIR
At closeNov 3, 2026, 4:02 PM EST
After hours · Nov 3, 4:02 PM ET
- YTD
- -84.02%
- 1 year
- -94.05%
- Market cap
- 3.86M
- Revenue (ttm)
- 1.78M
- EPS (ttm)
- -64.40
- Shares out
- 72.19M
- Forward P/E
- -0.98
- YTD return
- -84.02%
- 1-year return
- -94.05%
- Volume
- 19.00K
- Avg volume
- 216.76K
- Open
- 2.31
- Previous close
- 2.21
- Day's range
- 2.23 – 2.36
- 52-week range
- 2.05 – 53.20
- Beta
- -0.18
- Price target
- 2.50 (+7.8%)
- Earnings date
- Feb 10, 2025
2Y -189.75 (-98.83%)
Key statistics
- Enterprise value
- 20.89M
- PEG ratio
- 0.00
- Price / sales
- 17.87
- Price / book
- 0.81
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 1057.60%
- Free cash flow
- -28.54M
- Total cash
- 21.37M
- Total debt
- 17.70M
- Return on equity
- -219.18%
- Short % of float
- 2.27%
- 50-day average
- 0.4662
- 200-day average
- 0.799475
Analyst view
- Target (low)
- 1.00
- Target (mean)
- 2.50
- Target (high)
- 5.00
- Strong buy3
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 10, 2025
Expected Feb 10, 2025. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 10, 2025 | Dec 1, 2024 | -0.18 | — | — | — |
| Nov 11, 2024 | Sep 1, 2024 | -0.30 | -0.28 | +0.02 | +6.67% |
| Aug 6, 2024 | Jun 1, 2024 | -0.29 | -0.27 | +0.02 | +6.90% |
| Jun 24, 2024 | Mar 1, 2024 | -0.47 | -0.36 | +0.11 | +23.40% |
| Feb 12, 2024 | Dec 1, 2023 | -0.61 | -0.50 | +0.11 | +18.03% |
| Nov 13, 2023 | Sep 1, 2023 | -0.47 | -0.51 | -0.04 | -8.51% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2024 | Piper Sandler | main | Overweight | Overweight |
| Jun 25, 2024 | Piper Sandler | main | Overweight | Overweight |
| Jun 25, 2024 | BTIG | down | Buy | Neutral |
| Apr 30, 2024 | Truist Securities | main | Buy | Buy |
| Nov 14, 2023 | Truist Securities | main | Buy | Buy |
| Jul 28, 2023 | Piper Sandler | init | — | Overweight |
About Beyond Air, Inc.
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. In addition, the company develops ultra-high concentration NO in Phase 1 clinical trial to treat solid tumors. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- beyondair.net
News
Max Hospitality Selects Beyond Oil as Frying Standard Across Its Restaurants and Venues 
Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2026 
12 Health Care Stocks Moving In Tuesday's After-Market Session 
Beyond Oil Announces First Commercial Adoption in the Industrial Frying Segment - 12 Health Care Stocks Moving In Thursday's After-Market Session
Beyond Oil Enters the Romanian Market with Initial Order from New Distributor 
Duchess Restaurants Selects Beyond Oil as Frying Standard Across the Chain 
Beyond Oil Appoints Joe Colligan as Chief Executive Officer of Beyond Oil USA 
Beyond Air Affirms FY2027 Sales Guidance of $16.000M-$18.000M vs $16.715M Est 
Beyond Air Reports Q2 Preliminary Revenue Of ~$2.3M, Reiterates FY26 Revenue Range $16M - $18M
Your note
Sign in to keep a note on XAIR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AVNIEL AMIR | Officer and Director | Sale | Dec 27, 2023 | 0 |
| BENTSUR RON | Director | Purchase | Mar 19, 2023 | 144,736 |
| CAREY ROBERT F. | Director | Purchase | Sep 25, 2024 | 0 |
| FORBES WILLIAM P | Director | Purchase | Mar 30, 2023 | 14,855 |
| GAUL MICHAEL A | Chief Operating Officer | Purchase | Nov 15, 2023 | 88,150 |
| LARSON DOUGLAS QUINTON | Chief Financial Officer | Stock Award(Grant) | Mar 19, 2024 | 27,548 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Lasry, Marc | 6.85% | 4,946,697 | 2.18M | Sep 29, 2024 |
| AIGH Capital Management LLC | 4.99% | 3,602,991 | 1.59M | Sep 29, 2024 |
| Soros Fund Management LLC | 2.05% | 1,476,626 | 651.63K | Sep 29, 2024 |
| Vanguard Group Inc | 1.75% | 1,264,514 | 558.03K | Sep 29, 2024 |
| Bleichroeder LP | 1.02% | 738,313 | 325.82K | Sep 29, 2024 |
| Kingdon Capital Management LLC | 0.79% | 567,526 | 250.45K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.22% | 879,430 | 388.09K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.52% | 374,314 | 165.18K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.27% | 194,649 | 85.90K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.14% | 102,611 | 45.28K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.06% | 46,053 | 20.32K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 44,497 | 19.64K | Oct 30, 2024 |